TAO Synergies (TAOX) EBT Margin (2025 - 2026)
TAO Synergies' (TAOX) quarterly EBT Margin came in at 10492.37% in Q2 2026, up 43160955.0% on a YoY basis from N/an in Q2 2025, and down 1058.81% quarter-over-quarter from 1094.31% in Q1 2026.
Powered by 
Analysis
TAO Synergies (TAOX) EBT Margin (2025 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported EBT Margin for 2 consecutive years, with 10492.37% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBT Margin rose 43160955.0% year-over-year to 10492.37%; the trailing twelve-month figure through Jun 2026 stood at 2155.49% (changed N/A YoY), and the FY2025 full-year result was 9609.23%, changed N/A from the prior year.
- EBT Margin slipped to 10492.37% in Q2 2026 per TAOX's latest filing, from 1094.31% in the prior quarter.
- Across five years, EBT Margin topped out at 1094.31% in Q1 2026 and bottomed at 442101.92% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.50 Bn | 197.51 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 181.29 Bn | 178.11 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 82.55 Bn | 74.56 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 61.65 Bn | 56.47 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.65 Bn | 49.52 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 30.01 Bn | 30.01 Bn | 1.16 Mn | -20,427.46% |
| 10 | TAO Synergies | 30.79 Mn | 30.79 Mn | - | -10,492.37% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10,492.37% |
| Mar 31, 2026 | 1,094.31% |
| Dec 31, 2025 | -8,376.17% |
| Sep 30, 2025 | -1,929.11% |
| Jun 30, 2025 | -442,101.92% |